Skip to main content

Table 1 Summary of engraftment rates of PDX tumors

From: Patient-derived xenografts as compatible models for precision oncology

Tumor type Mice strain Implantation site Engraftment rate Engraftment-related factors References
Colorectal cancer NSG Subcutaneous 76%   Cho et al., 2019 [11]
  Nude Orthotopic 89%   Aytes et al., 2012 [12]
Pancreatic cancer (ductal adenocarcinoma) Nude Subcutaneous 45% Post-operation CA 19–9 level Chen et al., 2020 [13]
  ICR SCID Subcutaneous 67%   Mattie et al., 2013 [14]
Breast cancer SCID/Beige, NSG Mammary fat pad 19–21%   Zhang et al., 2013 [20]
  NOD/SCID Humanized mammary fat pad 13%   Li et al., 2013 [21]
Non-small cell lung cancer Nude, NOG Subcutaneous 41% Brain metastasis, SCC histology, tumor stage, wild-type EGFR Lee et al., 2015 [15]
  NOD/SCID Renal capsule 90%   Dong et al., 2010 [16]
Gastric cancer NOG Subcutaneous 24% Intestinal type, high tumor cell percentage, short procedure time Choi et al., 2016 [22]
Liver cancer (hepatocellular carcinoma) NSG Subcutaneous, orthotopic 14%   Zhu et al., 2020 [23]
Kidney cancer (renal cell carcinoma) NOD/SCID Orthotopic (Renal capsule) 37% Tumor stage, Tumor implanted from metastatic site Sivanand et al., 2012 [24]
Bladder cancer (urothelial carcinoma) BALB/ c-nu Subcutaneous 15%   Park et al., 2013 [25]
Biliary tract cancer (cholangiocarcinoma and gallbladder cancers) NOD/SCID Subcutaneous 54% Surgical resection, median ischemic time Leiting, 2020 [17]
Head and neck cancer (squamous cell carcinoma) NSG Subcutaneous 85% Lymph node positive Kimple et al., 2013 [18]
Medulloblastoma Rag2 SCID Orthotopic 52%   Zhao et al., 2012 [19]
Uveal melanoma NOD/SCID Subcutaneous 28% Metastasis Némati et al., 2010 [26]